The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions: A Comparison of Britain, Australia, and Canada
Abstract
CONTEXT: National public insurance for drugs is often based on evidence of comparative effectiveness and cost-effectiveness. This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been at the forefront of evidence-based coverage internationally. OBJECTIVES: To describe how clinical and cost-effectiveness evidence is used in coverage decisions both within and across jurisdictions and to identify common issues in the process of evidence-based coverage. DESIGN, SETTING, AND PARTICIPANTS: Descriptive analysis of retrospective data from the Common Drug Review (CDR) of Canada, National Institute for Health and Clinical Excellence (NICE) in Britain, and Pharmaceutical Benefits Advisory Committee (PBAC) of Australia. All publicly available information as of December 31, 2008, was gathered from each committee's Web site (data set begins in January 2004 [CDR], February 2001 [NICE], and July 2005 [PBAC]). MAIN OUTCOME MEASURE: Listing recommendations for each drug by disease indication. RESULTS: NICE recommended 87.4% (174/199) of submissions for listing compared with a listing rate of 49.6% (60/121) and 54.3% (153/282) for the CDR and PBAC, respectively. Significant uncertainty around clinical effectiveness, typically resulting from inadequate study design or the use of inappropriate comparators and unvalidated surrogate end points, was identified as a key issue in coverage decisions. Recommendations varied considerably across countries, possibly because of differences in the medications reviewed; different agency processes, including the willingness to negotiate on price; and the approach to "me too" drugs. The data suggest that the 3 agencies make recommendations that are consistent with evidence on effectiveness and cost-effectiveness but that other factors are often important. CONCLUSIONS: NICE, PBAC, and CDR face common issues with respect to the quality and strength of the experimental evidence in support of a clinically meaningful effect. However, comparative effectiveness and cost-effectiveness, along with other relevant factors, can be used by national agencies to support drug decision making. The results of the evaluation process in different countries are influenced by the context, agency processes, ability to engage in price negotiation, and perhaps differences in social values.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Devlin, N., & Parkin, D. (2004) · Health Economics · doi:10.1002/hec.864 · Cited by 709
Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?
Temple, R. (1999) · JAMA · doi:10.1001/jama.282.8.790 · Cited by 337
Hill, S. R., Mitchell, A. S., & Henry, D. A. (2000) · JAMA · doi:10.1001/jama.283.16.2116 · Cited by 224
Harris, A. H., Hill, S. R., Chin, G., Li, J. J., & Walkom, E. (2008) · Medical Decision Making · doi:10.1177/0272989x08315247 · Cited by 217
Self-citationPsaty, B. M. (1999) · JAMA · doi:10.1001/jama.282.8.786 · Cited by 187
A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response
Felson, D. T. (2007) · Arthritis Care & Research · doi:10.1002/art.22552 · Cited by 152
Drug Prices and Value for Money: The Australian Pharmaceutical Benefits Scheme
Henry, D. A., Hill, S. R., & Harris, A. (2005) · JAMA · doi:10.1001/jama.294.20.2630 · Cited by 113
Self-citationThe economics of end-stage renal disease care in Canada: incentives and impact on delivery of care
Manns, B., Mendelssohn, D. C., & Taub, K. J. (2007) · International Journal of Health Care Finance and Economics · doi:10.1007/s10754-007-9022-y · Cited by 109
Self-citationAmerican College of Physicians* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-12-200806170-00222 · Cited by 106
Cited by
Alonso-Coello, P., Schünemann, H. J., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., Treweek, S., Mustafa, R. A., Rada, G., Rosenbaum, S., et al. (2016) · BMJ · doi:10.1136/bmj.i2016 · Cited by 1,317
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M., & Ross, J. S. (2014) · JAMA · doi:10.1001/jama.2013.282034 · Cited by 407
Bending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 391
Angelis, A., Lange, A., & Kanavos, P. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-017-0871-0 · Cited by 305
Metadata
- Authors
- Clement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., & Manns, B. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-10-07
- Volume
- 302
- Issue
- 13
- Pages
- 1437
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1965870971
- Cited by
- 343
- References
- 23
- FWCI
- 73.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions: A Comparison of Britain, Australia, and Canada. https://app.cochat.ai/papers/10.1001/jama.2009.1409
- The paper
- Clement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., & Manns, B. J. (2009). Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions: A Comparison of Britain, Australia, and Canada. JAMA. https://doi.org/10.1001/jama.2009.1409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.